Condition: Esophageal Squamous Cell Carcinoma · Sponsor: Tianjin Medical University Cancer Institute and Hospital
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as adjuvant therapy, compared with neoadjuvant chemoradiotherapy and surgery for locally advanced ESCC in multicenter.
This description comes directly from the study's public registry record.
Hongjing Jiang, MD,PhD · 18622221069 · jianghongjing@tmu.edu.cn
Xiaobin Shang, MD,PhD · 18622221071 · shangxiaobin@tmu.edu.cn
Always discuss trial participation with your own doctor first.
| Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04807673